AP NEWS

Mymetics Presents New Data Regarding Cold Chain Independent Virosome Based Vaccines

November 14, 2018

EPALINGES, SWITZERLAND / ACCESSWIRE / November 14, 2018 / Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life-threatening and life disabling diseases, announces that

EPALINGES, SWITZERLAND / ACCESSWIRE / November 14, 2018 / Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life-threatening and life disabling diseases, announces that new data is presented today by Mymetics at the annual Mucosal Vaccines, Adjuvants and Delivery meeting in Lausanne, Switzerland.

Since 2015, Mymetics has been leading a consortium to develop thermostable and cold-chain independent virosome-based vaccines. The project, named MACIVIVA, is funded as part of Horizon 2020, the European Union research and innovation framework program and by the Swiss State Secretariat for Education, Research and Innovation (SERI), and has a total grant value of €8.4 million. With the MACIVIVA project, Mymetics has brought together the leading contract manufacturers and the relevant expertise for spray drying, freeze drying and analytical techniques from the pharmaceutical industry.

The late breaker presentation today, titled “Thermostable Virosome-based Vaccines Under New Solid Dosage Forms” will be presented by Dr. Sylvain Fleury, Mymetics’ CSO.

Dr. Fleury will present data showing that Mymetics’ HIV virosome-based candidate vaccine was successfully transformed into dry powder and into sublingual tablets. These new solid dosage forms were stored at 1 to 3 month time intervals at 4°C (40°F), 25°C (77°F) and 40°C (104°F) and the vaccine candidate maintained its structural integrity, while the liquid formulation showed structural degradation at 25°C (77°F) and 40°C (104°F). In pre-clinical in vivo studies, the nasal delivery of spray dried virosomes and oral delivery of the sublingual tablet showed to be a possible effective, needle-free route for immunization, triggering immune responses in not only the serum, but also in the mucosal immune compartments.

The MACIVIVA project will end this November 2018 and may receive up to €5.3 million funding from the European Union’s Horizon 2020 research and innovation program under Grant Agreement No 646122.

These promising results allow Mymetics to apply for new grants and possible collaborations to further advance its virosome-based vaccines into clinical development, in particular, its HIV-1 vaccine candidate.

About Mymetics

Mymetics Corporation (OTCQB:MYMX) is a Swiss-based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has several vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, malaria, Chikungunya and the RSV vaccine and several ongoing collaborative projects in the field of allergy and oncology Immunotherapy.

Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. For further information, please visit www.mymetics.com.

CONTACTS:

Mymetics Corporation

Ronald Kempers

CEO

Tel: +41 21 653 4535

Forward-looking statements

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements, which are identified by the words “believe,” “expect,” “anticipate,” “intend,” “plan” and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics’ most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date the statements were made.

SOURCE: Mymetics Corporation

AP RADIO
Update hourly